Fixed and Adaptive Parallel Subgroup-Specific Design for Survival Outcomes: Power and Sample Size (vol 7, 19, 2017) by Antoniou, Miranta et al.
Journal of
Personalized 
Medicine
Correction
Correction: Antoniou, M.; et al. Fixed and Adaptive
Parallel Subgroup-Specific Design for Survival
Outcomes: Power and Sample Size. J. Pers. Med. 2017,
7, 19
Miranta Antoniou 1,2,* ID , Andrea L. Jorgensen 1,2 and Ruwanthi Kolamunnage-Dona 1,2
1 MRC North West Hub for Trials Methodology Research, Liverpool L69 3GL, UK;
A.L.Jorgensen@liverpool.ac.uk (A.L.J.); Ruwanthi.Kolamunnage-Dona@liverpool.ac.uk (R.K.-D.)
2 Department of Biostatistics, Institute of Translational Medicine, University of Liverpool,
Liverpool L69 3GL, UK
* Correspondence: Miranta.Antoniou@liverpool.ac.uk; Tel.: +44-(0)151-794-9752
Received: 30 April 2018; Accepted: 2 May 2018; Published: 7 May 2018


The authors wish to make the following corrections to this paper [1], due to typographical errors:
On page 6, the sentence, “A time tij (i.e., sum of accrual time and follow-up time) is generated for
each patient, and if tij is greater than the cutoff time then it is assumed that the patient encountered
the event at tij, otherwise the patient’s event time is censored at tij” should be “A time tij (i.e., sum of
accrual time and follow-up time) is generated for each patient, and if tij is less than the cutoff time then
it is assumed that the event was observed at tij, otherwise the patient’s event time is censored at tij”.
They would also like to remove the word log rank in page 11 in the four following cases:
“For the biomarker-negative subgroup of the two-stage adaptive design which tests the efficacy
of the experimental treatment, the stopping rules are the following:
Stage 1: Reject the null hypothesis (stop for efficacy) if T’1− ≤ ε1−
Do not reject the null hypothesis (stop for futility) if T’1− > b1−
Continue to the second stage if ε1− < T’1− ≤ b1−
where 0 < ε1− < b1− ≤ 1 and T’1− refers to the log-rank test statistic in the biomarker-negative subgroup
at the first stage of the study,
Stage 2: Reject the null hypothesis (stop for efficacy) if T’2− ≤ ε2−
Do not reject the null hypothesis (stop for futility) if T’2− > ε2−
where T’2− refers to the log-rank test statistic in the biomarker-negative subgroup at the second stage
of the study.
For the biomarker-positive subgroup of the two-stage adaptive design which tests the efficacy of
the experimental treatment, the stopping rules are the following,
Stage 1: Reject the null hypothesis (stop for efficacy) if T’1+ ≤ ε1+
Do not reject the null hypothesis (stop for futility) if T’1+ > b1+
Continue to the second stage if ε1+ < T’1+ ≤ b1+
where 0 < a1+ < b1+ ≤ 1 and T’1+ refers to the log-rank test statistic in the biomarker-positive subgroup
at the first stage of the study,
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Stage 2: Reject the null hypothesis (stop for efficacy) if T’2+ ≤ ε2+
Do not reject the null hypothesis (stop for futility) if T’2+ > ε2+
where T’2+ refers to the log-rank test statistic in the biomarker-positive subgroup at the second stage
of the study.”
These changes have no material impact on the conclusions of the paper. The authors would like
to apologize for any inconvenience caused to the readers by these changes.
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